CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC

Introduction: Canakinumab is a human monoclonal anti–interleukin-1β antibody with the potential to enhance the activity of programmed death-ligand 1 inhibitors by inhibiting protumor inflammation. Methods: CANOPY-N was a randomized, phase 2 study to evaluate safety and efficacy of neoadjuvant canaki...

Full description

Saved in:
Bibliographic Details
Main Authors: Jay M. Lee, MD, Jean-Louis Pujol, MD, PhD, Jun Zhang, MD, PhD, Oleg Leonov, MD, PhD, Masahiro Tsuboi, MD, PhD, Edward S. Kim, MD, MBA, Calvin Ng, MD, Nicolas Moreno-Mata, MD, PhD, Amy Cummings, MD, PhD, Ilhan Hacibekiroglu, MD, Abidin Sehitogullari, MD, Nirmal Veeramachaneni, MD, Cathy Spillane, PhD, Jiawei Duan, PhD, Claudia Bossen, PhD, Alexander Savchenko, MD, PhD, Chiara Lobetti-Bodoni, MD, PhD, Tony Mok, MD, Pilar Garrido, MD
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:JTO Clinical and Research Reports
Subjects:
NSCLC
Neoadjuvant treatment
Monoclonal antibodies
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000761
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364325000761

Similar Items